Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Long term clinical performance and analytical robustness of the Lumipulse plasma p-tau217 assay in routine clinical practice.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ashrafzadeh-Kian Susan, Figdore Daniel J, Bornhorst Joshua A, Vanderboom Patrick M, Callison Sarah, Day Gregory S, Lachner Christian, Graff-Radford Neill, Shir Dror, Jack Clifford R, Knopman David S, Graff-Radford Jonathan, Petersen Ronald C, Ramanan Vijay K, Algeciras-Schimnich Alicia
Аннотация
INTRODUCTION: Plasma phosphorylated tau 217 (p‑tau217) immunoassays are increasingly being used to assess Alzheimer's disease (AD) pathology despite limited data affirming test reliability over time.
METHODS: Clinical performance of the Fujirebio Lumipulse G p‑tau217 assay was assessed in 744 Mayo Clinic patients presenting for evaluation of cognitive impairment between July 2024 and December 2025. Cerebrospinal fluid p‑tau181/amyloid beta 42 or amyloid positron emission tomography, within 1 year of p-tau217 testing, were used as reference. Analytical robustness was evaluated by tracking result frequencies over time, conducting quality control checks, performing 10 lot‑to‑lot comparisons, and comparing two versions of reagents.
RESULTS: Diagnostic accuracy for detection of AD pathology was 93% (95% confidence interval 91-95) with 23% intermediate results. Reduced estimated glomerular filtration rate was associated with increased intermediate results among amyloid-negative individuals. Result frequencies remained stable, average imprecision was 8%, and analytical bias between lots and version changes were ≤ 11%.
DISCUSSION: The findings support plasma p-tau217 reliability in clinical practice for evaluation of cognitively impaired individuals.
METHODS: Clinical performance of the Fujirebio Lumipulse G p‑tau217 assay was assessed in 744 Mayo Clinic patients presenting for evaluation of cognitive impairment between July 2024 and December 2025. Cerebrospinal fluid p‑tau181/amyloid beta 42 or amyloid positron emission tomography, within 1 year of p-tau217 testing, were used as reference. Analytical robustness was evaluated by tracking result frequencies over time, conducting quality control checks, performing 10 lot‑to‑lot comparisons, and comparing two versions of reagents.
RESULTS: Diagnostic accuracy for detection of AD pathology was 93% (95% confidence interval 91-95) with 23% intermediate results. Reduced estimated glomerular filtration rate was associated with increased intermediate results among amyloid-negative individuals. Result frequencies remained stable, average imprecision was 8%, and analytical bias between lots and version changes were ≤ 11%.
DISCUSSION: The findings support plasma p-tau217 reliability in clinical practice for evaluation of cognitively impaired individuals.